IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 141 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.41 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,561,515 | -74.6% | 343,190 | -60.6% | 0.00% | -66.7% |
| Q2 2023 | $6,139,605 | +5.7% | 872,103 | -8.3% | 0.00% | +50.0% |
| Q1 2023 | $5,810,806 | +172.3% | 951,032 | +184.8% | 0.00% | +100.0% |
| Q4 2022 | $2,133,627 | +29.9% | 333,901 | +94.7% | 0.00% | 0.0% |
| Q3 2022 | $1,643,000 | -13.2% | 171,500 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,893,000 | +74.5% | 171,500 | +163.2% | 0.00% | – |
| Q1 2022 | $1,085,000 | -77.6% | 65,160 | -74.3% | 0.00% | -100.0% |
| Q4 2021 | $4,843,000 | -16.8% | 253,707 | +7.5% | 0.00% | 0.0% |
| Q3 2021 | $5,821,000 | +105.8% | 236,042 | +117.2% | 0.00% | +100.0% |
| Q2 2021 | $2,828,000 | -96.2% | 108,676 | -95.4% | 0.00% | -97.0% |
| Q1 2021 | $75,218,000 | -9.3% | 2,375,814 | +33.0% | 0.03% | -15.4% |
| Q4 2020 | $82,895,000 | +107.6% | 1,786,529 | +47.3% | 0.04% | +85.7% |
| Q3 2020 | $39,926,000 | +6.0% | 1,212,810 | -11.6% | 0.02% | -4.5% |
| Q2 2020 | $37,679,000 | -12.2% | 1,372,629 | -4.2% | 0.02% | -29.0% |
| Q1 2020 | $42,909,000 | -17.2% | 1,433,392 | -23.4% | 0.03% | +6.9% |
| Q4 2019 | $51,812,000 | +58.9% | 1,871,836 | +4.5% | 0.03% | +45.0% |
| Q3 2019 | $32,599,000 | +16.9% | 1,791,137 | +57.5% | 0.02% | +17.6% |
| Q2 2019 | $27,892,000 | +1202.8% | 1,137,519 | +405.3% | 0.02% | +1600.0% |
| Q1 2019 | $2,141,000 | +61.2% | 225,100 | +50.0% | 0.00% | 0.0% |
| Q4 2018 | $1,328,000 | -18.8% | 150,100 | +3.2% | 0.00% | 0.0% |
| Q3 2018 | $1,636,000 | -12.1% | 145,400 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,861,000 | -49.0% | 145,400 | -32.7% | 0.00% | -66.7% |
| Q1 2018 | $3,652,000 | +640.8% | 216,100 | +250.8% | 0.00% | – |
| Q4 2017 | $493,000 | +3.4% | 61,600 | 0.0% | 0.00% | – |
| Q3 2017 | $477,000 | +5.3% | 61,600 | 0.0% | 0.00% | – |
| Q2 2017 | $453,000 | – | 61,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 3,876,600 | $127,618,000 | 11.48% |
| Fairmount Funds Management LLC | 596,890 | $19,650,000 | 8.32% |
| Ghost Tree Capital, LLC | 575,000 | $18,929,000 | 5.47% |
| Perceptive Advisors | 10,085,632 | $332,019,000 | 4.85% |
| Avoro Capital Advisors LLC | 9,536,039 | $313,926,000 | 4.46% |
| FRAZIER MANAGEMENT LLC | 1,312,999 | $43,224,000 | 3.88% |
| ACUTA CAPITAL PARTNERS, LLC | 315,000 | $10,370,000 | 2.82% |
| Orbimed Advisors | 6,645,100 | $218,757,000 | 2.75% |
| QVT Financial LP | 572,971 | $18,862,000 | 2.30% |
| Prosight Management, LP | 120,606 | $3,970,000 | 1.89% |